Abstract | BACKGROUND/AIMS: METHODS: A rat model of peritoneal dialysis was induced by a daily intraperitoneal infusion of 4.25% Dianeal. Those rats were treated with Rho-kinase inhibitor, fasudil. Immunofluorescence, Western blot and RT-PCR were used to detect the expression of TGF-β1, Collagen I, αSMA and VEGF in each group. Microvessel density (MVD) was measured by immunohistochemistry. Rho-kinase activity was determined by western immunoblotting. RESULTS:
Rho-kinase was activated in the peritoneum of the PD group, which was inhibited by fasudil. Compared with PD group, the mRNA and protein expressions of TGF-β1, αSMA and Collagen I were significantly downregulated in fasudil treatment groups in a dose-dependent manner, and the expression of VEGF and peritoneal MVD was also significantly downregulated in fasudil treatment groups in a dose-dependent manner. CONCLUSION:
|
Authors | Weisheng Peng, Qiaoling Zhou, Xiang Ao, Rong Tang, Zhou Xiao |
Journal | Renal failure
(Ren Fail)
Vol. 35
Issue 7
Pg. 958-66
(Aug 2013)
ISSN: 1525-6049 [Electronic] England |
PMID | 23859538
(Publication Type: Journal Article)
|
Chemical References |
- Actins
- Collagen Type I
- Dialysis Solutions
- Protein Kinase Inhibitors
- Transforming Growth Factor beta1
- Vascular Endothelial Growth Factor A
- smooth muscle actin, rat
- 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
- rho-Associated Kinases
- fasudil
|
Topics |
- 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
(analogs & derivatives, pharmacology)
- Actins
(metabolism)
- Animals
- Collagen Type I
(metabolism)
- Dialysis Solutions
(pharmacology)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Gene Expression Regulation
(drug effects)
- Male
- Microvessels
(drug effects, pathology)
- Neovascularization, Pathologic
(drug therapy, etiology, metabolism, physiopathology)
- Peritoneal Dialysis
(adverse effects)
- Peritoneal Fibrosis
(drug therapy, etiology, metabolism, physiopathology)
- Peritoneum
(blood supply, drug effects, metabolism, pathology)
- Protein Kinase Inhibitors
(pharmacology)
- Rats
- Rats, Sprague-Dawley
- Transforming Growth Factor beta1
(metabolism)
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(metabolism)
- rho-Associated Kinases
(antagonists & inhibitors, metabolism)
|